Loading stock data…
Castle Biosciences (CSTL)
$24.68-0.80 (-3.12%)
Market ClosedLast close Jul 24
Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), atopic dermatitis (AD), and uveal melanoma.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Castle Biosciences, Inc. in the Healthcare sector is trading at $24.68 with a market capitalization of $626M. Wall Street consensus targets $42.78 (9 analysts), implying a +73.3% move over the next 12 months. The stock is currently 44% below its 52-week high of $44.28, remaining 14.3% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +73.3% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $83.68M↓ | $87.01M↑ | $83.04M↓ | $86.19M↓ | $87.99M |
| Gross Profit | $63.15M↓ | $68.69M↑ | $64.34M↓ | $68.56M↓ | $71.61M |
| Operating Income | -$18.41M↓ | -$3.83M↑ | -$6.80M↓ | -$4.25M↑ | -$27.93M |
| Net Income | -$14.52M↓ | -$2.33M↓ | -$501,000↓ | $4.52M↑ | -$25.85M |
Peer Comparison
JNJUNHPFE
Fundamentals
Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), atopic dermatitis (AD), and uveal melanoma. The company offers DecisionDx-Melanoma, ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$625.56M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-2.78%
Volume
Today's trading volume
393,431
Recent News
SkylineDx’s Merlin CP-GEP Granted FDA Breakthrough Device Designation
By Karen Roman SkylineDx said the FDA granted Breakthrough Device Designation to Merlin CP-GEP, the company’s gene expression profile test for risk assessment and clinical decision-making in patients with early-stage cutaneous melanoma. The Merlin CP-GEP is the first and only melanoma gene expression profiling test to have this FDA designation and to be included in […] The post SkylineDx’s Merlin CP-GEP Granted FDA Breakthrough Device Designation appeared first on ExecEdge.
Castle Biosciences (CSTL) Stock Sees Split Analyst Revisions As Price Targets Come Down
For Castle Biosciences, recent analyst moves have pulled some price targets down from earlier levels in the US$50 range into the mid US$30s and US$40 area. These changes line up with a more cautious tone in Street commentary, where optimism around growth and profitability is tempered by questions about how quickly the company can convert testing volumes into sustained earnings. As you read on, you will see how to interpret these shifting targets and follow the evolving narrative around Castle...
How The Castle Biosciences (CSTL) Investment Story Is Evolving Without Fresh Analyst Commentary
The latest update on Castle Biosciences leaves the current price target unchanged, indicating that covering analysts have not adjusted their formal expectations at this time. With no new analyst commentary provided alongside this update, the story is being shaped more by the absence of fresh views than by new opinions. In the sections that follow, you will see how to track this kind of quiet period and what it might mean for staying on top of the evolving narrative around the stock. Analyst...
How The Castle Biosciences (CSTL) Story Is Shifting After Solid Q1 And Lower Targets
The modeled fair value estimate for Castle Biosciences has been trimmed from US$47.25 to US$45.88, a reduction of about 2.9% in the price target. That shift lines up with recent Street research, where solid Q1 execution is being weighed against more cautious assumptions on what investors should pay for the stock. As you read on, you will see how these updated targets fit into the evolving analyst narrative and what that might mean for your own view on the shares. Stay updated as the Fair...
Castle Biosciences, Inc. Q1 2026 Earnings Call Summary
Moby summary of Castle Biosciences, Inc.'s Q1 2026 earnings call